The drug NovoRapid is a short-acting human insulin analogue. It is used for type I and II diabetes. Stimulates processes inside cells, synthesis of fatty acids, reduces the production of glucose by the liver.
1 pencil contains 100 units of insulin aspart.
Additional components: glycerolum, fenol, actrapid HM, zinc chloridum, n atriichloridium, etc.
The drug is produced in the form of an injection liquid in special syringes-pencils with caps, 3.5 mg each. One pencil is 1 dose of the drug, which lasts 3-5 hours.
The drug NovoRapid is a short-acting human insulin analogue. It is used for type I and II diabetes. Stimulates processes inside cells, synthesis of fatty acids, reduces the production of glucose by the liver. The active ingredient is insulin aspart 100 IU, in which, unlike human insulin, the amino acid L-proline is replaced by D-aspartic acid. Thanks to this replacement, the drug has an ultra-fast and short-term effect in relation to conventional insulin. It is absorbed from the fat layer much faster, and lowers glucose levels at a faster rate. The effect of the drug is noted within 10-20 minutes after application. In this case, the effect of the drug lasts for 3-5 hours. Much less likely to develop nocturnal hypoglycemia when using the drug. The possibility of daytime hypoglycemia also does not increase, since the drug is completely interchangeable with human insulin.
Indications for use
Indications for use of NovoRapid are:
- type I diabetes mellitus;
- type II diabetes mellitus;
- hyperglycemic coma (prevention).
The presence of increased sensitivity to the constituents of the drug.
There is no data on the method of use by children under 6 years of age.
Pregnancy and breastfeeding period
There is insufficient data on the safety of the drug during pregnancy. There are no restrictions when breastfeeding. The drug does not affect the reaction and psychomotor function, but with a low sugar level, concentration and reaction speed may be impaired.
Mode of application
NovoRapid is intended for parenteral administration. The dosage is determined by the attending physician, based on the glucose levels. It is prescribed mainly in combination with drugs that are longer in effect. The introduction is carried out in the area of the thigh, shoulder, buttocks, groin. The most effective insertion site is the anterior abdominal wall (groin). The injection sites need to be changed from time to time. Usually, the dosage for children and adults is from 0.5 to 1.0 U / kg per day. It is necessary to administer the medicine before meals, in which case the drug will reimburse 50-70% of insulin, and the remainder will be replenished with long-acting agents.
Intravenous administration of the drug, if necessary, is carried out by qualified medical personnel.
With prolonged administration of excessive doses of the drug, there is a risk of developing hyperglycemia. Mild hyperglycemia is eliminated on its own by taking the required amount of glucose as food. To do this, it is advisable to always have something sweet with you. More severe cases of hyperglycemia require 1 mg of glucagon intramuscularly or glucose (dextrose) 40% intravenously. In severe cases of overdose, medical supervision is required.
During the use of the drug, hypoglycemia may develop, the signs of which are:
- excessive sweating;
- feeling tired;
- lowering pressure;
Also, while taking the drug, the following reactions may occur:
- skin rashes;
- gastrointestinal disorders;
- difficulty breathing;
- lowering pressure;
- fatty degeneration (rare).
The medicine must be stored away from light, at a temperature of 5 to 8 degrees. Avoid freezing. The drug used must be stored at a temperature not exceeding 30 degrees; it should not be stored in the refrigerator, since it should be at room temperature when administered.